Prognostic Significance of Immunocytometric Count of Medullar Blasts in Myelodysplastic Syndromes

被引：0
|
作者：
Molteni, Alfredo
Speziale, Valentina
Riva, Marta
Nichelatti, Michele
Greco, Rosa
Cesana, Clara [1 ]
Scarpati, Barbara [2 ]
Morra, Enrica
机构：
[1] Osped Niguarda Ca Granda, Transfus Unit, Milan, Italy
[2] Osped Niguarda Ca Granda, Transfus Unit, Milan, Italy
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4945.4945
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4945
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance
    Passam, FH
    Tsirakis, G
    Boula, A
    Fragou, A
    Consolas, I
    Alegakis, A
    Kyriakou, DS
    Alexandrakis, MG
    CLINICAL AND LABORATORY HAEMATOLOGY, 2004, 26 (06): : 391 - 395
  • [42] Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes
    Takagi, S
    Tanaka, O
    Origasa, H
    Miura, Y
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 277 - 283
  • [43] Expression and prognostic significance of Bcl-2 family proteins in Myelodysplastic syndromes
    Boudard, D
    Vasselon, C
    Berthéas, MF
    Jaubert, J
    Mounier, C
    Reynaud, J
    Viallet, A
    Chautard, S
    Guyotat, D
    Campos, L
    AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (02) : 115 - 125
  • [44] PROGNOSTIC-SIGNIFICANCE OF CHROMOSOMAL-ABNORMALITIES IN ACUTE LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES
    YUNIS, JJ
    BRUNNING, RD
    CLINICS IN HAEMATOLOGY, 1986, 15 (03): : 597 - 620
  • [45] Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes
    Luo, SS
    Ogata, K
    Yokose, N
    Kato, T
    Dan, K
    STEM CELLS, 2000, 18 (02) : 112 - 119
  • [46] Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts
    Patnaik, Mrinal M.
    Hanson, Curtis A.
    Sulai, Nanna
    Hodnefield, Janice M.
    Knudson, Ryan A.
    Ketterling, Rhett P.
    Lasho, Terra L.
    Tefferi, Ayalew
    BLOOD, 2011, 118 (21) : 1624 - 1625
  • [47] Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?)
    Bennett, John M.
    Tuechler, Heinz
    Aul, Carlo
    Strupp, Corinna
    Germing, Ulrich
    LEUKEMIA RESEARCH, 2016, 47 : 63 - 69
  • [48] Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts
    Arenillas, Leonor
    Calvo, Xavier
    Luno, Elisa
    Senent, Leonor
    Alonso, Ester
    Ramos, Fernando
    Ardanaz, Maria Teresa
    Pedro, Carme
    Tormo, Mar
    Marco, Victor
    Montoro, Julia
    Diez-Campelo, Maria
    Brunet, Salut
    Arrizabalaga, Beatriz
    Xicoy, Blanca
    Andreu, Rafael
    Bonanad, Santiago
    Jerez, Andres
    Nomdedeu, Meritxell
    Ferrer, Ana
    Sanz, Guillermo
    Florensa, Lourdes
    BLOOD, 2016, 128 (22)
  • [49] Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count
    Jacobs, Nisha L.
    Holtan, Shernan G.
    Porrata, Luis F.
    Markovic, Svetomir N.
    Tefferi, Ayalew
    Steensma, David P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (03) : 160 - 163
  • [50] Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
    Itzykson, Raphael
    Crouch, Simon
    Travaglino, Erica
    Smith, Alex
    Symeonidis, Argiris
    Hellstrom-Lindberg, Eva
    Sanz, Guillermo
    Cermak, Jaroslav
    Stauder, Reinhard
    Elena, Chiara
    Germing, Ulrich
    Mittelman, Moshe
    Langemeijer, Saskia
    Madry, Krzysztof
    Tatic, Aurelia
    Holm, Mette Skov
    Almeida, Antonio Medina
    Savic, Aleksander
    Simec, Njetocka Gredelj
    Luno, Elise
    Culligan, Dominic
    Guerci-Bresler, Agnes
    Malcovati, Luca
    van Marrewijk, Corine
    Bowen, David
    de Witte, Theo
    Fenaux, Pierre
    BLOOD ADVANCES, 2018, 2 (16) : 2079 - 2089
12345